RT Journal Article
SR Electronic
T1 Late-breaking abstract: Genomic variation as a predictor of smoking behaviour and smoking cessation treatment toxicity
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P1807
VO 44
IS Suppl 58
A1 Stamatoula Tsikrika
A1 Sofia Vakali
A1 Nantia Flora
A1 Cristiana Pavlidis
A1 Athanassios Vozikis
A1 Theodoros Giannakopoulos
A1 George Patrinos
A1 Christina Gratziou
YR 2014
UL http://erj.ersjournals.com/content/44/Suppl_58/P1807.abstract
AB Introduction: Smoking is a major public health problem and is the single largest cause of preventable death in the world, contributing to >5 million deaths a year. The persistence of smoking can be attributed to multiple diverse causes, the most important being genetic risk factors contributing to smoking behavior.Aim: It has been demonstrated that genetic factors account for approximately 40–75% of the variation in smoking initiation, 70–80% of the variation in smoking maintenance, about 50% of the variance in cessation success and 30–50% of the variance in risk of withdrawal symptoms.Methods: We have attempted to shed light into the possible correlation of genomic variants with (a) smoking addiction, and (b) response to smoking cessation treatment with varenicline, a prescription medication used to treat nicotine addiction. Genomic DNA was isolated from saliva, obtained with consent from 80 smokers, 60 non-smokers and 100 ethnically matched control individuals of Hellenic origin. We have subsequently genotyped these individuals for the following markers: rs1329650 and rs1028936 in the CHRNA3 gene, previously correlated with nicotine dependence, rs6265 in the BDNF gene and rs1051730 in the DBH gene, previously correlated with smoking initiation and cessation, respectively, and the rs555018, rs1190449, rs6495309, in the CHRN gene family, which were previously reported as pharmacogenomic biomarkers to predict adverse reactions in varenicline treatment.Conclusion: Data related to the correlation of these genomic biomarkers with smoking addiction, and response to smoking cessation treatment with varenicline will be presented.